Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP/PS1 mice

11 Feb 2021

Abstract excerpt

R deficiency can mediate several beneficial effects against AD pathogenesis, and genetic/pharmacological ablation of this protein could be a potential therapeutic option for AD.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Neuroinflammation and Neurodegeneration Mechanisms
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33591941
DOI: 10.18632/aging.202501

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP/PS1 micePMID 33591941Read ↗

Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease.Semantic proximity Read ↗

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's DiseaseSemantic proximity Read ↗

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeuticsSemantic proximity Read ↗

A CRISPR/Cas9 based strategy to manipulate the Alzheimer’s amyloid pathwaySemantic proximity Read ↗

CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavageSemantic proximity Read ↗

Application of CRISPR/Cas9 in the management of Alzheimer’s disease and Parkinson’s disease: a reviewSemantic proximity Read ↗

Long term rescue of Alzheimer’s deficits <i>in vivo</i> by one-time gene-editing of <i>App</i> C-terminusSemantic proximity Read ↗

Depletion of the AD risk gene <i>SORL1</i> selectively impairs neuronal endosomal traffic independent of amyloidogenic APP processingSemantic proximity Read ↗

<i>In vivo</i> evidence that <i>SORL1</i> , encoding the endosomal recycling receptor SORLA, can function as a causal gene in Alzheimer’s DiseaseSemantic proximity Read ↗

CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutationSemantic proximity Read ↗

Precise and efficient insertion of A673T mutation in APP gene using MSYMSemantic proximity Read ↗

Mutations in APP and their role in beta-amyloid deposition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.